

23104080D

SENATE BILL NO. 1533

Senate Amendments in [] - February 7, 2023

A *BILL to amend and reenact § 54.1-3442.6 of the Code of Virginia, relating to medical marijuana program; additional cultivation facility.*

Patron Prior to Engrossment—Senator Deeds

Referred to Committee on Rehabilitation and Social Services

Be it enacted by the General Assembly of Virginia:**1. That § 54.1-3442.6 of the Code of Virginia is amended and reenacted as follows:****§ 54.1-3442.6. Permit to operate pharmaceutical processor or cannabis dispensing facility.**

A. No person shall operate a pharmaceutical processor or a cannabis dispensing facility without first obtaining a permit from the Board. The application for such permit shall be made on a form provided by the Board and signed by a pharmacist who will be in full and actual charge of the pharmaceutical processor's dispensing area or cannabis dispensing facility. The Board shall establish an application fee and other general requirements for such application.

B. Each permit shall expire annually on a date determined by the Board in regulation. The number of permits that the Board may issue or renew in any year is limited to one pharmaceutical processor and up to five cannabis dispensing facilities for each health service area established by the Board of Health. Permits shall be displayed in a conspicuous place on the premises of the pharmaceutical processor and cannabis dispensing facility.

C. The Board shall adopt regulations establishing health, safety, and security requirements for pharmaceutical processors and cannabis dispensing facilities. Such regulations shall include requirements for (i) physical standards; (ii) location restrictions; (iii) security systems and controls; (iv) minimum equipment and resources; (v) recordkeeping; (vi) labeling, including the potency of each botanical cannabis product and the amounts recommended by the practitioner or dispensing pharmacist, and packaging; (vii) routine inspections no more frequently than once annually; (viii) processes for safely and securely dispensing and delivering in person cannabis products to a patient, his registered agent, or, if such patient is a minor or a vulnerable adult as defined in § 18.2-369, such patient's parent or legal guardian; (ix) dosage limitations for cannabis oil that provide that each dispensed dose of cannabis oil not exceed 10 milligrams of delta-9-tetrahydrocannabinol; (x) a process for the wholesale distribution of and the transfer of usable cannabis, botanical cannabis, cannabis oil, and cannabis products between pharmaceutical processors, between a pharmaceutical processors and a cannabis dispensing facility, and between cannabis dispensing facilities; (xi) an allowance for the sale of devices for administration of dispensed cannabis products and hemp-based CBD products that meet the applicable standards set forth in state and federal law, including the laboratory testing standards set forth in subsection M; (xii) an allowance for the use and distribution of inert product samples containing no cannabinoids for patient demonstration exclusively at the pharmaceutical processor or cannabis dispensing facility, and not for further distribution or sale, without the need for a written certification; (xiii) a process for acquiring industrial hemp extracts and formulating such extracts into cannabis products; and (xiv) an allowance for the advertising and promotion of the pharmaceutical processor's products and operations, which shall not limit the pharmaceutical processor from the provision of educational material to practitioners who issue written certifications and patients. The Board shall also adopt regulations for pharmaceutical processors that include requirements for (a) processes for safely and securely cultivating Cannabis plants intended for producing cannabis products, (b) the secure disposal of agricultural waste, and (c) a process for registering cannabis oil products.

D. The Board shall require that, after processing and before dispensing any cannabis products, a pharmaceutical processor shall make a sample available from each batch of cannabis product for testing by an independent laboratory located in Virginia meeting Board requirements. A valid sample size for testing shall be determined by each laboratory and may vary due to sample matrix, analytical method, and laboratory-specific procedures. A minimum sample size of 0.5 percent of individual units for dispensing or distribution from each homogenized batch of cannabis oil is required to achieve a representative cannabis oil sample for analysis. A minimum sample size, to be determined by the certified testing laboratory, from each batch of botanical cannabis is required to achieve a representative botanical cannabis sample for analysis. Botanical cannabis products shall only be tested for the following: total cannabidiol (CBD); total tetrahydrocannabinol (THC); terpenes; pesticide chemical residue; heavy metals; mycotoxins; moisture; and microbiological contaminants. Testing thresholds shall be consistent with generally accepted cannabis industry thresholds. The pharmaceutical processor may

ENGROSSED

SB1533E

59 remediate botanical cannabis or cannabis oil that fails any quality testing standard except pesticides.
60 Following remediation, all remediated botanical cannabis or cannabis oil shall be subject to laboratory
61 testing and approved upon satisfaction of applicable testing standards, which shall not be more stringent
62 than initial testing prior to remediation. If a batch of botanical cannabis fails retesting after remediation,
63 it shall be considered usable cannabis and may be processed into cannabis oil. Stability testing shall not
64 be required for any cannabis product with an expiration date assigned by the pharmaceutical processor
65 of six months or less from the date of the cannabis product registration approval. Stability testing
66 required for assignment of an expiration date longer than six months shall be limited to microbial
67 testing, on a pass/fail basis, and potency testing, on a 10 percent deviation basis, of active ingredients.

68 E. A laboratory testing samples for a pharmaceutical processor shall obtain a controlled substances
69 registration certificate pursuant to § 54.1-3423 and shall comply with quality standards established by the
70 Board in regulation.

71 F. Every pharmaceutical processor's dispensing area or cannabis dispensing facility shall be under the
72 personal supervision of a licensed pharmacist on the premises of the pharmaceutical processor or
73 cannabis dispensing facility. The pharmaceutical processor shall ensure that security measures are
74 adequate to protect the cannabis from diversion at all times, and the pharmacist-in-charge shall have
75 concurrent responsibility for preventing diversion from the dispensing area.

76 Every pharmaceutical processor shall designate a person who shall have oversight of the cultivation
77 and production areas of the pharmaceutical processor and shall provide such information to the Board.
78 The Board shall direct all communications related to enforcement of requirements related to cultivation
79 and production of cannabis oil products by the pharmaceutical processor to such designated person.

80 G. The Board shall require the material owners of an applicant for a pharmaceutical processor or
81 cannabis dispensing facility permit to submit to fingerprinting and provide personal descriptive
82 information to be forwarded along with his fingerprints through the Central Criminal Records Exchange
83 to the Federal Bureau of Investigation for the purpose of obtaining criminal history record information
84 regarding the applicant's material owners. The cost of fingerprinting and the criminal history record
85 search shall be paid by the applicant. The Central Criminal Records Exchange shall forward the results
86 of the criminal history background check to the Board or its designee, which shall be a governmental
87 entity. A pharmaceutical processor shall maintain evidence of criminal background checks for all
88 employees and delivery agents of the pharmaceutical processor. Criminal background checks of
89 employees and delivery agents may be conducted by any service sufficient to disclose any federal and
90 state criminal convictions.

91 H. In addition to other employees authorized by the Board, a pharmaceutical processor may employ
92 individuals who may have less than two years of experience (i) to perform cultivation-related duties
93 under the supervision of an individual who has received a degree in a field related to the cultivation of
94 plants or a certification recognized by the Board or who has at least two years of experience cultivating
95 plants, (ii) to perform extraction-related duties under the supervision of an individual who has a degree
96 in chemistry or pharmacology or at least two years of experience extracting chemicals from plants, and
97 (iii) to perform duties at the pharmaceutical processor and cannabis dispensing facility upon certification
98 as a pharmacy technician.

99 I. A pharmaceutical processor to whom a permit has been issued by the Board may (i) establish up
100 to five cannabis dispensing facilities, *subject to the permit requirement set forth in subsection B*, for the
101 dispensing of cannabis products that have been cultivated and produced on the premises of a
102 pharmaceutical processor permitted by the Board and (ii) [*in the case of a pharmaceutical processor*
103 *located in Health Service Area III,*] *establish one additional location at which the pharmaceutical*
104 *processor may cultivate cannabis plants.* Each cannabis dispensing facility and the additional cultivation
105 location shall be located within the same health service area as the pharmaceutical processor.

106 J. No person who has been convicted of a felony under the laws of the Commonwealth or another
107 jurisdiction within the last five years shall be employed by or act as an agent of a pharmaceutical
108 processor or cannabis dispensing facility.

109 K. Every pharmaceutical processor or cannabis dispensing facility shall adopt policies for
110 pre-employment drug screening and regular, ongoing, random drug screening of employees.

111 L. A pharmacist at the pharmaceutical processor's dispensing area and the cannabis dispensing facility
112 shall determine the number of pharmacy interns, pharmacy technicians, and pharmacy technician trainees
113 who can be safely and competently supervised at one time; however, no pharmacist shall supervise more
114 than six persons performing the duties of a pharmacy technician at one time in the pharmaceutical
115 processor's dispensing area or cannabis dispensing facility.

116 M. A pharmaceutical processor may acquire industrial hemp extracts grown and processed in
117 Virginia, and in compliance with state or federal law, from a registered industrial hemp dealer or
118 processor. A pharmaceutical processor may process and formulate such extracts into an allowable dosage
119 of cannabis product. Industrial hemp extracts acquired and formulated by a pharmaceutical processor are
120 subject to the same third-party testing requirements that may apply to cannabis plant extract. Testing

shall be performed by a laboratory located in Virginia and in compliance with state law governing the testing of cannabis products. The industrial hemp dealer or processor shall provide such third-party testing results to the pharmaceutical processor before industrial hemp extracts may be acquired.

N. With the exception of § 2.2-4031, neither the provisions of the Administrative Process Act (§ 2.2-4000 et seq.) nor public participation guidelines adopted pursuant thereto shall apply to the adoption of any regulation pursuant to this section. Prior to adopting any regulation pursuant to this section, the Board of Pharmacy shall publish a notice of opportunity to comment in the Virginia Register of Regulations and post the action on the Virginia Regulatory Town Hall. Such notice of opportunity to comment shall contain (i) a summary of the proposed regulation; (ii) the text of the proposed regulation; and (iii) the name, address, and telephone number of the agency contact person responsible for receiving public comments. Such notice shall be made at least 60 days in advance of the last date prescribed in such notice for submittals of public comment. The legislative review provisions of subsections A and B of § 2.2-4014 shall apply to the promulgation or final adoption process for regulations pursuant to this section. The Board of Pharmacy shall consider and keep on file all public comments received for any regulation adopted pursuant to this section.

O. The Board shall register all cannabis products that meet testing, labeling, and packaging standards.

ENGROSSED

SB1533E